Literature DB >> 31069565

Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.

Mithalesh Kumar Singh1, Lata Singh2, Neelam Pushker3, Neeru Saini4, Rachna Meel3, Kunzang Chosdol5, Sameer Bakhshi6, Seema Sen1, Pradeep Venkatesh3, Bhavna Chawla3, Jasbir Kaur7, Seema Kashyap8.   

Abstract

Inflammation in uveal melanoma (UM) is linked to a bad prognosis. It is rare type of cancer, of which the metastases are usually fatal within a year. Infiltration with an inflammatory infiltrate increases with disease progression but does not seem to inhibit metastasis. The Canonical NFκB (C-NFκB) pathway is known to play a crucial role in tumor inflammation. We therefore, studied the expression of canonical NFκB proteins and their prognostic relevance in UM. Our study evaluated the expression of C-NFκB proteins (p65, p50, and c-Rel) by using immunohistochemistry on sections from 75 formalin-fixed UM. Activation of the NFκB subunit was determined on fresh tumor specimens by measuring the DNA-binding activity in nuclei using an NFκB ELISA assay. Real-time PCR was performed on frozen material on 58 tumors. The presence of native C-NFκB heterodimers (p65/p50 and c-Rel/p50) was confirmed by co-immunoprecipitation followed by Western blotting. We observed a high nuclear immunoreactivity of p65, p50, and c-Rel proteins in 54, 60 and 41% UM cases, respectively. Expression of C-NFκB proteins significantly correlated with parameters which are related to the inflammatory environment of UM. Nuclear immunoreactivity of p65 and p50 was associated with lower patient survival (p = 0.041; p = 0.048) while c-Rel was not. Our finding reveals that C-NFκB proteins expressed are more often in UM with inflammation than those without inflammation. Activation of the canonical NFκB pathway is more frequent in high risk UM patients. These observations might help to understand the behaviour of high risk tumors, with upregulation of C-NFκB proteins contributing to tumor aggressiveness.

Entities:  

Keywords:  Immunohistochemistry; Inflammation; NFκB; Uveal melanoma; c-Rel/p50 heterodimer; p65/p50

Mesh:

Substances:

Year:  2019        PMID: 31069565     DOI: 10.1007/s10585-019-09969-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

Review 1.  The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling.

Authors:  M Karin; M Delhase
Journal:  Semin Immunol       Date:  2000-02       Impact factor: 11.130

Review 2.  NF-kappaB in cancer: from innocent bystander to major culprit.

Authors:  Michael Karin; Yixue Cao; Florian R Greten; Zhi-Wei Li
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

Review 3.  Immunology of intraocular tumors.

Authors:  Jerry Y Niederkorn; Shixuan Wang
Journal:  Ocul Immunol Inflamm       Date:  2005-02       Impact factor: 3.070

4.  Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma.

Authors:  D I Tai; S L Tsai; Y H Chang; S N Huang; T C Chen; K S Chang; Y F Liaw
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

5.  Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.

Authors:  T Mäkitie; P Summanen; A Tarkkanen; T Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

6.  The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24.

Authors:  Barbara S Hawkins
Journal:  Am J Ophthalmol       Date:  2004-12       Impact factor: 5.258

7.  Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma.

Authors:  Judit Pallares; Jose Luis Martínez-Guitarte; Xavier Dolcet; David Llobet; Montserrat Rue; José Palacios; Jaime Prat; Xavier Matias-Guiu
Journal:  J Pathol       Date:  2004-12       Impact factor: 7.996

8.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

Authors:  Eli Pikarsky; Rinnat M Porat; Ilan Stein; Rinat Abramovitch; Sharon Amit; Shafika Kasem; Elena Gutkovich-Pyest; Simcha Urieli-Shoval; Eithan Galun; Yinon Ben-Neriah
Journal:  Nature       Date:  2004-08-25       Impact factor: 49.962

9.  Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence.

Authors:  Jeffrey S Ross; Bhaskar V S Kallakury; Christine E Sheehan; Hugh A G Fisher; Ronald P Kaufman; Prabhjot Kaur; Karen Gray; Bradley Stringer
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

Review 10.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

View more
  2 in total

Review 1.  MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance.

Authors:  Maria Chiara Gelmi; Laurien E Houtzagers; Thomas Strub; Imène Krossa; Martine J Jager
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

Review 2.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.